期刊文献+

骨质疏松症治疗药物的研究进展 被引量:8

Research Progress in Therapeutic Drugs against Osteoporosis
下载PDF
导出
摘要 骨质疏松症是以骨量减少、骨的微观结构退化为特征,致使骨的脆性增加并易于发生骨折的一种全身性骨骼疾病,是当前严重危害人类特别是绝经妇女和老人的疾病之一。近年来出现了许多预防和治疗骨质疏松症的药物,极大地推动了骨质疏松症理论基础的完善和临床治疗研究。就该领域的研究进展进行了简要综述。 Osteoporosis is a general bone disease characterized by low bone mass and microarchitectural deterioration of bone tissue, which lead to bone fragility and a consequent susceptibility to fracture. It is one of serious diseases, which endangers health of humans, particularly postmenopausal women and old men. In recent years, a lot of drugs have been developed for prevention and treatment of osteoporosis and also largely promote development of clinical research and theoretics of osteoporosis. This article summarizes the overall development in therapeutic drugs against osteoporosis.
出处 《畜牧与饲料科学》 2011年第4期127-128,共2页 Animal Husbandry and Feed Science
基金 大连民族学院"太阳鸟"项目
关键词 骨质疏松 治疗药物 复合治疗 osteoporosis therapeutic drugs compound therapy
  • 相关文献

参考文献10

  • 1RYMER J, ROBINSON J, FOGELMAN I. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausa| bone loss [ J ] .Osteoporos Int, 2001,12 (6) : 478-483.
  • 2BROWN J P, KENDLER D L, McCLUNG M R, et al. The ef- ficacy and tolerability of risedronate once a week for the treat- ment of postmenopausal osteoporosis [J].Calcif Tissue Int, 2002,71 (2) : 103-111.
  • 3DE GROEN P C, LUBBE D F, HIRSCH L J, et al. Esophagi- tis associated with the use of alendronate [J ].N Engl J Med, 1996,335(14): 1016-1021.
  • 4HODSMAN A B, KISIEL M, ADACHI J D, et al. Histomor- phometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH (1-34) therapy in women with severe osteoporosis [J].Bone, 2000,27(2) :311-318.
  • 5李铁军,于世凤,王晓敏,庞淑珍.1,25-二羟基维生素D_3对小鼠骨髓细胞形成破骨细胞样细胞及其骨吸收效应的影响[J].中国骨质疏松杂志,2000,6(3):12-15. 被引量:20
  • 6刘群,冉忠梅,张庆哲.中药防治骨质疏松症的研究进展[J].云南中医中药杂志,2003,24(3):49-50. 被引量:8
  • 7YANG N N, VENUGOPALAN M, HARDIKAR S, et al. I- dentification of an estrogen response element activated by metabolites of 17 β-estradiol and raloxifene [J].Science, 1996,273 (5279) : 1222- 1225.
  • 8LINDSAY R, COSMAN F, LOBO R A, et al. Addition of al- endronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial [ J ]. J Clin Endocrinol Metab, 1999,84 (9) : 3076-3081.
  • 9JOHNELL O, SCHEELE W, LU Y, et al. Effects of raloxifene (RLX) ,alendronate (ALN) and RLX + ALN on bone mineral density (BMD) and biochemical markers of bone turnover in postmenopausal women with osteoporosis [J].J Bone Miner Res, 1999,14(Suppl 1) :S157.
  • 10COSMAN F, NIEVES J, WOELFERT L, et al. Parathyroid hormone added to established hormone therapy: effects on ver- tebral fracture and maintenance of bone mass after parathyroid hormone withdrawal [ J ] .J Bone Miner Res, 2001 , 16 ( 5 ) : 925- 931.

二级参考文献25

共引文献26

同被引文献43

引证文献8

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部